Six-Year Single-Center Experience with ECMO Use in Various Strategies for Lung Transplantation, Including COVID-19 Patients.

J Clin Med · 2025 · PMC12194707 · PMID 40565939

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Early (60-day) and long-term (two-year) survival analysis showed a trend towards worse survival in the group of COVID-19 patients supported with ECMO and undergoing LuTx vs. patients undergoing LuTx with ECMO, but without COVID-19, and it was 55.6% vs. 87.0% and 33.3% vs. 55.4%, respectively ( Figure 11 ). 3.7.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.